200 Participants Needed

Empathetic Communication for Patient Preference

CT
Overseen ByClinical Trials Referral Office
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Mayo Clinic
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Survey in the clinical trial Empathetic Communication for Patient Preference?

The research suggests that patient-centered communication, which involves understanding and incorporating patient preferences, is a key component of high-quality healthcare. Although there is no direct evidence about the treatment Survey, the emphasis on patient-centered communication could imply that treatments focusing on patient preferences may improve patient experiences and outcomes.12345

Is empathetic communication for patient preference generally safe for humans?

The research articles provided do not contain specific safety data about empathetic communication for patient preference or related treatments like Survey. They focus on communication practices and patient preferences rather than safety outcomes.678910

How is the treatment 'Empathetic Communication for Patient Preference' different from other treatments?

This treatment focuses on improving patient satisfaction by emphasizing empathetic communication and meeting both emotional and medical needs, which is different from traditional approaches that often prioritize biomedical communication styles.12111213

What is the purpose of this trial?

This study aims to evaluate whether patients have different preference patterns for empathetic communication through AI vs human-being when knowledge of authorship is known vs blinded.

Research Team

AC

April Christensen, MD, MS

Principal Investigator

Mayo Clinic in Rochester

Eligibility Criteria

This trial is for individuals interested in participating in a study about communication preferences. There are no specific inclusion or exclusion criteria provided, which suggests that the study may be open to a broad adult population.

Inclusion Criteria

I am over 18, seeing a palliative care doctor, and have been diagnosed with cancer.

Exclusion Criteria

I am able to understand and consent to my own medical treatment.
Major psychiatric disorders including, but not limited to, bipolar disorder, psychotic disorders, active substance use disorder, and patients with active suicidal or homicidal thoughts. NOTE: Patients with history of normal grieving reactions, major unipolar depressive disorder, posttraumatic stress disorder or generalized anxiety disorder would NOT be excluded
Inability to read in English

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Survey

Participants complete a survey to assess preference patterns for empathetic communication

1 day
1 visit (in-person or virtual)

Follow-up

Participants are monitored for any changes in preference patterns after the survey

4 weeks

Treatment Details

Interventions

  • Survey
Trial Overview The trial is testing patient preferences for empathetic communication authored by AI versus humans. Participants will likely take surveys where they'll evaluate messages without knowing who wrote them and then again with that knowledge.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Survey Group - UnblindedExperimental Treatment1 Intervention
Participants will be informed of origin of survey statements
Group II: Survey Group - BlindedExperimental Treatment1 Intervention
Participants will be blinded to origin of survey statements

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials
3,427
Recruited
3,221,000+

Findings from Research

A survey of 433 physicians and 1,000 American adults revealed a significant disagreement on the timing of medical safety communications, with physicians generally opposing early signal postings while the public favored them.
Over 25% of the public indicated they would stop taking their medication if they found it listed on the FDA's Adverse Event Reporting System, highlighting the need for better communication strategies that consider public perception and understanding.
Transparency and the Food and Drug Administration--a quantitative study.Lofstedt, R., Bouder, F., Chakraborty, S.[2013]

References

A new, brief questionnaire (PEQ) developed in primary health care for measuring patients' experience of interaction, emotion and consultation outcome. [2022]
Patient-centered communication: do patients really prefer it? [2022]
There is Little or No Association Between Independently Assessed Communication Strategies and Patient Ratings of Clinician Empathy. [2023]
Measuring patient-centered communication in patient-physician consultations: theoretical and practical issues. [2022]
Making better decisions: from measuring to constructing preferences. [2022]
Patient Preference for Aggressive Medication Therapies with Potentially Stronger Adverse Drug Reactions Revealed Using a Scenario-based Survey. [2017]
Transparency and the Food and Drug Administration--a quantitative study. [2013]
Adverse drug reactions: when the risk becomes a reality for patients. [2021]
Do physicians communicate the adverse effects of medications that older patients want to hear? [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
How should effectiveness of risk communication to aid patients' decisions be judged? A review of the literature. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
Humor and other communication preferences in physician-patient encounters. [2019]
How Do Patients Define Satisfaction? The Role of Patient Perceptions of Their Participation and Health Provider Emotional Expression. [2021]
An online survey to study the relationship between patients' health literacy and coping style and their preferences for self-management-related information. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security